Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2026)

Jazz Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• In Q1 2026, Operating Leases rose 21.97% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 21.97% YoY), while the FY2025 annual figure was $50.9 million, up 30.72% from the prior year.
• Operating Leases for Q1 2026 stood at $47.3 million, down from $50.9 million in the prior quarter.
• The five-year high for Operating Leases was $83.1 million in Q1 2022, with the low at $38.8 million in Q1 2025.
• The 5-year median for Operating Leases is $61.9 million (2023), against an average of $61.4 million.
• The sharpest annual moves came in 2022 and 2025: Operating Leases sank 50.28% in 2022, then surged 30.72% in 2025.
• Jazz Pharmaceuticals' Operating Leases stood at $71.8 million in 2022, then fell by 17.56% to $59.2 million in 2023, then plunged by 34.25% to $38.9 million in 2024, then surged by 30.72% to $50.9 million in 2025, then retreated by 7.07% to $47.3 million in 2026.
• Business Quant data shows JAZZ's Operating Leases at $47.3 million in Q1 2026, $50.9 million in Q4 2025, and $53.4 million in Q3 2025.